Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Colorectal Cancer Clinical Trial

Official title:

Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03638206
• Other study ID #: 2018ZDYFY-BinDeDBD
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 1, 2018
• Est. completion date: March 1, 2023

Study information

• Verified date: December 2019
• Source: Shenzhen BinDeBio Ltd.
• Contact: ZhongHua Yang
• Phone: 18938688105
• Email: zh.yang[@]bindebio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

Description:

The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include ten different tumor-specific antibody.They are as following:anti-CD19 antibody for B cell leukemia and lymphoma;anti-CD22 antibody for B cell leukemia and lymphoma;anti-CD33 antibody for myeloid leukemia;anti-BCMA antibody for multiple myeloma;anti-CD38 antibody for multiple myeloma;anti-NY-ESO-1 antibody for multiple myeloma,esophagus cancer,lung cancer,melanoma and synovial sarcoma;anti-DR5 antibody for hepatoma;anti-C-met antibody for hepatoma,colorectal cancer,ovarian cancer and renal carcinoma;anti-EGFR V III antibody for hepatoma,lung cancer and glioma;anti-Mesothelin antibody for gastric cancer,pancreatic cancer and mesothelioma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 73
• Est. completion date: March 1, 2023
• Est. primary completion date: March 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 70 Years

Eligibility

Inclusion Criteria:

1. If patients had receive immunotherapy, they should reach PR/NR, or recurrency.

2. Patients must be willing to sign an informed consent.

3. age: 4 to 70 years

4. Estimated survival of = 12 weeks, but = 2 years

5. Blood tumor or solid tumor was diagnosed by histopathology.Positive expression of CD19, CD22, CD33, CD38, BCMA, NY-ESO-1, c-met, Mesothelin, CEGFRvIII and DR5 was confirmed by biopsy IHC test or flow cytometry test. If NY-ESO-1 is positive expression ,positive HLA-A*0201 is required at the same time .

6. Subjects with solid tumor must have measureable disease

7. Routine blood test:hemoglobin>=90 g/L; platelet>=50×10^9/L.

8. Renal function:BUN: 9-20mg / dl; serum creatinine<= 1.5 times upper limits of normal; endogenous creatinine clearance rate>=50 ml/min

9. Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV(patients with liver cancer were excluded)

10. Cardiac function: stable hemodynamic and left ventricular ejection fraction (LVEF)>=55%.

11. ECOG score =2

12. Adequate venous access for apheresis, and no other contraindications for leukapheresis

13. Women of child-bearing age must have evidence of negative pregnancy test.

14. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol.

Exclusion Criteria:

1. ECOG >= 3

2. Patients with history of T cell tumors

3. Patients with severe insufficient cardiac, pulmonary and hepatorenal functions

4. Acute or chronic GVHD after allogeneic hematopoiesis

5. steroid hormoneswere used before and after blood collection and infusion

6. HIV infection or active hepatitis B or hepatitis C infection

7. Uncontrolled active infection

8. Enrolled to other clinical study in the last 4 weeks.

9. Subjects with systemic auto-immune disease or immunodeficiency.

10. Subjects with CNS diseases.

11. Other patients that researchers considered unsuitable for inclusion

Related Conditions & MeSH terms

• B-cell Acute Lymphoblastic Leukemia
• Burkitt Lymphoma
• Carcinoma, Renal Cell
• Colorectal Cancer
• Esophageal Neoplasms
• Esophagus Cancer
• Gastric Cancer
• Glioma
• Hepatoma
• Kidney Neoplasms
• Leukemia
• Lung Cancer
• Lymphoma
• Melanoma
• Mesothelioma
• Multiple Myeloma
• Myeloid Leukemia
• Ovarian Cancer
• Pancreatic Cancer
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Renal Carcinoma
• Sarcoma, Synovial
• Synovial Sarcoma

Intervention

Biological:
• CAR-T cell immunotherapy
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Shenzhen BinDeBio Ltd.	The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0	Safety evaluation	60 months
Secondary	Clinical response	Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, magnetic resonance imaging.	60 months
Secondary	CAR-T cells testing	The level of CAR-T cells will be tested regularly by Real-time Quantitative Polymerase Chain Reaction Detecting System(qPCR) or Flow cytometry to evaluate the proliferation in vivo and long-term survival.	60 months